Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Non-Hodgkin's LymphomaChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 28
- Registration Number
- NCT00864942
- Locations
- 🇺🇸
Georgetown University Hospital/Lombardi Cancer Center, Washington, District of Columbia, United States
Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 6
- Registration Number
- NCT00863850
- Locations
- 🇳🇱
Please Call For Information, Amsterdam, Netherlands
Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors
- Conditions
- Metastatic CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Other: laboratory biomarker analysisProcedure: Surgical Resection of Brain MetastasesRadiation: Stereotactic body radiation therapy
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- John Grecula
- Target Recruit Count
- 18
- Registration Number
- NCT00837928
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2018-04-17
- Target Recruit Count
- 11
- Registration Number
- NCT00834678
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Pharmatech
- Target Recruit Count
- 61
- Registration Number
- NCT00831597
- Locations
- 🇺🇸
Pharmatech Oncology Study Site, Richardson, Texas, United States
A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 137
- Registration Number
- NCT00825149
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
- Conditions
- Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Neoplasm
- Interventions
- Other: Quality-of-Life Assessment
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 45
- Registration Number
- NCT00823797
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
- Conditions
- Diffuse Large B-Cell LymphomaFollicular LymphomaNon-Hodgkin's LymphomaMantle Cell Lymphoma
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT00794638
Bendamustine in Acute Leukemia and MDS
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Lymphoblastic LeukemiaChronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00790855
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 564
- Registration Number
- NCT00769522
- Locations
- 🇩🇪
Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.